Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee

被引:157
作者
Bakker, AC
Joosten, LAB
Arntz, OJ
Helsen, MMA
Bendele, AM
vandeLoo, FAJ
vandenBerg, WB
机构
[1] AMGEN INC,BOULDER,CO
[2] UNIV NIJMEGEN HOSP,NL-6500 HB NIJMEGEN,NETHERLANDS
来源
ARTHRITIS AND RHEUMATISM | 1997年 / 40卷 / 05期
关键词
D O I
10.1002/art.1780400517
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To determine the efficacy of local human interleukin-l receptor antagonist (HuIL-1Ra) gene therapy in murine collagen-induced arthritis (CLA). Methods. DBA/1 mice were immunized against bovine type II collagen, Before the onset of arthritis, NIH/3T3 fibroblasts transfected with pMFG-IRAP were transplanted into the knee cavity, Normal NIH/3T3 cells served as controls, Paws were evaluated macroscopically for redness, swelling, and deformities during the course of arthritis, Swelling of the knee joints was measured by external gamma counting of (99m)technetium accumulation in the joint. Paws and knee joints were dissected and processed for histologic studies to evaluate inflammation and cartilage destruction. Results. The NIH/3T3 fibroblasts survived in the joint cavity of DBA mice for at least 7 days. The transduced cells expressed immunoreactive and bioactive HuIL-1Ra in the knee joint, and produced sufficient amounts to block the effect of 1 ng of recombinant murine IL-1 alpha on chondrocyte proteoglycan synthesis. The onset of CIA was almost completely prevented in knee joints containing HuIL-1Ra-producing cells, whereas joints containing normal cells showed severe inflammation and destruction of cartilage. Moreover, onset of CIA in the draining joints (ipsilateral paws) of the HuIL-1Ra gene-bearing knees was also prevented. Conclusion. Local production of HuIL-1Ra in the knee was able to ameliorate the effects of IL-1 on cartilage and could prevent the onset of CW not only in that knee, but also in the ''draining'' paw. This indicates the feasibility of gene transfer as a therapeutic approach to modulating arthritis.
引用
收藏
页码:893 / 900
页数:8
相关论文
共 24 条
  • [1] GENE-TRANSFER TO SYNOVIOCYTES - PROSPECTS FOR GENE TREATMENT OF ARTHRITIS
    BANDARA, G
    ROBBINS, PD
    GEORGESCU, HI
    MUELLER, GM
    GLORIOSO, JC
    EVANS, CH
    [J]. DNA AND CELL BIOLOGY, 1992, 11 (03) : 227 - 231
  • [2] INTRAARTICULAR EXPRESSION OF BIOLOGICALLY-ACTIVE INTERLEUKIN-1 RECEPTOR-ANTAGONIST PROTEIN BY EX-VIVO GENE-TRANSFER
    BANDARA, G
    MUELLER, GM
    GALEALAURI, J
    TINDAL, MH
    GEORGESCU, HI
    SUCHANEK, MK
    HUNG, GL
    GLORIOSO, JC
    ROBBINS, PD
    EVANS, CH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) : 10764 - 10768
  • [3] Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis
    Campion, GV
    Lebsack, ME
    Lookabaugh, J
    Gordon, G
    Catalano, M
    Borenstein, D
    Caldwell, J
    Cohen, SA
    Cohen, SB
    Fleischmann, R
    Heller, MD
    Howard, P
    Jaffer, AM
    Kaine, JL
    Kitsis, E
    Kopp, EJ
    Moreland, LW
    OHanlan, M
    Prupas, M
    Rosenberg, A
    Rutstein, J
    Sack, MR
    Schiff, MH
    Singleton, CM
    Taborn, J
    Tindall, E
    Weaver, AL
    Yocum, D
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (07): : 1092 - 1101
  • [4] DREVLOW B, 1993, ARTHRITIS RHEUM, V36, pS39
  • [5] RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS
    ELLIOTT, MJ
    MAINI, RN
    FELDMANN, M
    KALDEN, JR
    ANTONI, C
    SMOLEN, JS
    LEEB, B
    BREEDVELD, FC
    MACFARLANE, JD
    BIJL, H
    WOODY, JN
    [J]. LANCET, 1994, 344 (8930) : 1105 - 1110
  • [6] SYNOVIAL INTERLEUKIN-1 RECEPTOR ANTAGONIST AND INTERLEUKIN-1 BALANCE IN RHEUMATOID-ARTHRITIS
    FIRESTEIN, GS
    BOYLE, DL
    YU, C
    PAINE, MM
    WHISENAND, TD
    ZVAIFLER, NJ
    AREND, WP
    [J]. ARTHRITIS AND RHEUMATISM, 1994, 37 (05): : 644 - 652
  • [7] GEIGER T, 1993, CLIN EXP RHEUMATOL, V11, P515
  • [8] HUNG GL, 1994, GENE THER, V1, P64
  • [9] IVANYI D, 1987, J NATL CANCER I, V79, P149
  • [10] JOOSTEN LAB, 1994, CLIN EXP IMMUNOL, V97, P204